ACADIA Pharmaceuticals Inc. vs Rockwell Automation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B), while Rockwell Automation trades at $450 (market cap $49.64B). The key difference: Rockwell Automation is far larger — about 9.8× ACADIA Pharmaceuticals Inc.'s market cap, and Rockwell Automation pays a 1.23% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ROK | |
|---|---|---|
Market Cap | $5.07B | $49.64B |
Sector | Health | Industrials |
52-Week High | $29.41 | $495.08 |
52-Week Low | $20.06 | $333.75 |
Enterprise Value | $4.19B | $52.77B |
Dividend Yield | — | 1.23% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →